



GE Healthcare  
Life Sciences  
Pharmaceutical Diagnostics

100 Results Way  
Marlborough, MA 01752

October 31, 2018

Dear Valued Customer:

**Subject: Manufacturing Announcement Regarding Metastron™ (Strontium-89 Chloride Injection)**

I am writing to inform you that GE Healthcare has made the decision to cease the manufacture of Metastron, effective December 17, 2018.

Metastron is indicated for the relief of bone pain in patients with painful skeletal metastases. While we regret that we will no longer be able to offer this product as part of our portfolio, different molecular imaging tracers are available and may, in some circumstances, be appropriate for order through our GE Healthcare Nuclear Pharmacies.

The last-calibration date for Metastron will be January 11, 2019, and the product's expiration date will be February 8, 2019. Ordering deadlines remain unchanged.

We want to reassure you that GE Healthcare remains committed to nuclear medicine and continues to invest in new molecular imaging products as well as the development of innovative service solutions.

We greatly value your business and apologize for any inconvenience this may cause.

If you have any questions or concerns, please do not hesitate to reach out to your local GE Healthcare Nuclear Pharmacy, or our Medical Affairs Department at 800 654 0118 (option 2, then option 3).

Sincerely,

A handwritten signature in black ink, appearing to read 'Axel Grippo'.

Axel Grippo, General Manager  
GE Healthcare, US Nuclear Pharmacy Services